eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company’s lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
Metrics to compare | EFTR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEFTRPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −4.7x | −0.5x | |
PEG Ratio | 0.00 | −0.01 | 0.00 | |
Price/Book | 0.0x | 2.1x | 2.6x | |
Price / LTM Sales | 0.0x | 9.6x | 3.2x | |
Upside (Analyst Target) | 0.0% | 178.3% | 41.9% | |
Fair Value Upside | Unlock | 6.7% | 4.3% | Unlock |